MAPT and Alzheimer disease: In a longitudinal multicentre prognostic study with 1431 participants (673 cognitively unimpaired, 443 MCI and 315 AD all with positive Aβ status), baseline tau PET (18F-flortaucipir or 18F-FRO948) could predict change in mini-mental state examination (MMSE) over a period of almost two years and outperformed amyloid PET and MRI volumetric measures, suggestive that tau PET has a prognostic value in preclinical and prodromal AD [193].